Table S1, Table S2, Table S3, Table S4 from Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts
Year: 2024
Type: other
Abstract: Supplementary Table 1: Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Patient biomarkers/NGS has four categories: (+), (-), N/A, and Gain Supplementary Table 2: Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Supplementary Table 3. Event-free survival of PDXs compared to patient response. Event-free survival of PDXs compared to patient response. Supplementary Table 4. Immunohistochemistry antibodies.
Authors: Timothy P. DiPeri, Kurt W. Evans, Bailiang Wang, Ming Zhao, Argun Akcakanat, Maria Gabriela Raso, Yasmeen Q. Rizvi, Xiaofeng Zheng, Anil Korkut, Kaushik Varadarajan, Burak Uzunparmak, Ecaterina E. Dumbrava, Shubham Pant, Jaffer A. Ajani, Paula R. Pohlmann, V. Behrana Jensen, Milind Javle, Jordi Rodon, Funda Meric-Bernstam
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4396576651